Pompe disease, a genetic disorder, is commonly treated with enzyme-replacement therapy (ERT) requiring costly weekly infusions. Despite ERT’s groundbreaking nature, many patients face barriers accessing this crucial treatment. Factors like insurance coverage, state regulations, and pre-existing conditions impact access, particularly for those without insurance or in underserved regions. Without equitable access, the potential benefits of […]